Virpax Pharmaceuticals, Inc.

VRPX

US9282512063

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-15 EDT			5-day change	1st Jan Change
1.07 ^USD	-21.32%		-3.60%	-66.57%

07-10	Virpax Pharmaceuticals, Inc. Announces Positive Results of Swine Model Pilot Study for Probudur	CI
07-10	Wall Street Set to Open Slightly Higher Wednesday Ahead of Powell Testimony	MT

Virpax Pharmaceuticals Secures $2.5 Million Loan Financing and an Agreement with an Institutional Investor to Negotiate Additional Funding

July 08, 2024 at 07:30 am

Virpax Pharmaceuticals, Inc. announced that it has closed a $2.5 million secured loan financing from an institutional investor which enabled the final payment of its litigation settlement.

Latest news about Virpax Pharmaceuticals, Inc.

Virpax Pharmaceuticals, Inc. Announces Positive Results of Swine Model Pilot Study for Probudur	07-10	CI
Wall Street Set to Open Slightly Higher Wednesday Ahead of Powell Testimony	07-10	MT
Virpax Says Non-Narcotic Pain Medication Shows Positive Results in Swine Model Study; Shares Rise	07-10	MT
Virpax Pharmaceuticals, Inc. Announces Board and Committee Changes	07-08	CI
Virpax Pharmaceuticals Secures $2.5 Million Loan Financing and an Agreement with an Institutional Investor to Negotiate Additional Funding	07-08	CI
Virpax Pharmaceuticals, Inc. announced that it has received $2.5 million in funding	07-04	CI
Maxim Downgrades Virpax Pharmaceuticals to Hold From Buy	05-22	MT
Virpax Prices Public Offering of Shares, Warrants; Shares Tumble	05-15	MT
Top Premarket Decliners	05-15	MT
Investors Await Key Inflation Data for April as US Futures Remain Flat in Wednesday's Premarket	05-15	MT
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
Virpax Pharmaceuticals, Inc. Announces Resignation of Jeffrey Gudin as Chief Medical Officer and Executive Vice President	05-02	CI
Virpax Pharmaceuticals, Inc. Announces Results of Maximum Tolerated Dose Study for Probudur	04-30	CI
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-26	CI
Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs	03-15	MT
Virpax Pharmaceuticals Announces Preliminary Results of Probudurtm Pilot Study with the U.S. Army Institute of Surgical Research	02-07	CI
Virpax Pharmaceuticals Stockholders Approve Reverse Stock Split Plan; Shares Fall	12-29	MT
Virpax Pharmaceuticals Announces Leadership Transition	11-17	CI
Virpax Pharmaceuticals, Inc. Announces CEO Changes	11-16	CI
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-16	CI
Virpax Pharmaceuticals Announces Envelta Remains on Track for Trial in Humans Following FDA Review	23-10-31	CI
Virpax Names Gerald Bruce as CEO of Novvae Pharmaceuticals Unit	23-10-02	MT
Novvae Pharmaceuticals Announces Executive Appointments	23-10-02	CI
Virpax Forms New Unit Novvae Pharmaceuticals	23-09-18	MT
Virpax Pharmaceuticals, Inc Announces the Formation of Novvae? Pharmaceuticals	23-09-18	CI

Chart Virpax Pharmaceuticals, Inc.

Duration

Period

More charts

Virpax Pharmaceuticals, Inc. is a preclinical-stage pharmaceutical company. The Company is focused on developing novel and proprietary drug delivery systems across various pain indication. Its drug-delivery systems and drug-releasing technologies being developed are focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system (CNS) disorders to enhance patientsâ quality of life. Its portfolio consists of multiple preclinical stage product candidates: Epoladerm, Probudur, Envelta, AnQlar and NobrXiol. Probudur is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain. Envelta is an intranasal molecular envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. The NobrXiol is being developed for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of rare pediatric epilepsy.

Sector

Biotechnology & Medical Research

Calendar

2024-08-11 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1.07 USD

Average target price

20 USD

Spread / Average Target

+1,769.16%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
VIRPAX PHARMACEUTICALS, INC.	-66.57%	2.93M
MODERNA, INC.	+22.15%	46.56B
LONZA GROUP AG	+45.04%	41.67B
IQVIA HOLDINGS INC.	-2.37%	41.16B
ALNYLAM PHARMACEUTICALS, INC.	+33.84%	32.4B
CELLTRION, INC.	-6.35%	28.1B
ICON PUBLIC LIMITED COMPANY	+20.42%	28.18B
UNITED THERAPEUTICS CORPORATION	+48.83%	14.52B
MEDPACE HOLDINGS, INC.	+45.00%	13.74B
BIO-TECHNE CORPORATION	+0.06%	12.17B

Other Biotechnology & Medical Research

Virpax Pharmaceuticals, Inc.

Equities

VRPX

US9282512063

Biotechnology & Medical Research

Virpax Pharmaceuticals Secures $2.5 Million Loan Financing and an Agreement with an Institutional Investor to Negotiate Additional Funding

Latest news about Virpax Pharmaceuticals, Inc.

Chart Virpax Pharmaceuticals, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research